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Summary
Objective: To evaluate biological markers as potential quantitative traits of clinical osteoarthritis (OA) in a large multigenerational family in the
Carolinas of the USA known as the CARRIAGE (CARolinas Region Interaction of Aging, Genes and Environment) family.
Methods: During a series of three family reunions over 6 years, we ascertained 365 family members. We performed clinical hand examinations
(n¼ 287), and obtained sera (n¼ 278) for seven OA-related biomarkers [type IIA collagen N-propeptide (PIIANP), type II procollagen carboxy-
propeptide (CPII), neoepitope from cleavage of CII (C2C), cartilage oligomeric matrix protein (COMP), hyaluronan (HA), high-sensitive
C-reactive protein (hs-CRP), and glycated serum protein (GSP)]. Three hand OA deﬁnitions were evaluated e clinical ACR (American College
of Rheumatology) and GOGO (Genetics of Generalized OA) criteria, and any single hand joint involvement. Non-hand OA was deﬁned as
a negative hand examination for OA but varying prevalence of joint symptoms; the control group was deﬁned as having neither symptoms
nor evidence for clinical hand OA.
Results: Mean ln HA, ln COMP, and ln hs-CRP were signiﬁcantly higher in the hand OA group, compared with the non-hand OA or control
group. Adjusted for age and sex, mean ln PIIANP (a collagen II synthesis marker) was signiﬁcantly lower in the hand OA group compared
with the other groups. Among those without clinical hand OA, GSP was associated with hand joint symptoms.
Conclusions: This is the ﬁrst report, to our knowledge, showing an association of OA biomarkers and hand OA based on physical examination
alone. Analyses using these biomarkers as quantitative traits could reveal novel genetic loci and facilitate exploration of the genetic suscep-
tibility to OA.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common joint disorder caus-
ing chronic disability in the USA and worldwide1,2. By the
year 2030, an estimated 22% of Americans will be affected
by arthritis3. OA is regarded as a multifactorial disorder with
both environmental and genetic components4; however, the
exact pathogenesis remains unknown. Recently, the ge-
netic contribution to OA has been increasingly recognized
and studied. To date, through whole genome-wide linkage
scans, approximately 23 different loci in 14 chromosomes1Funding: This work was funded through the NIH/NIA (Claude D.
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1054have been reported to link to various OA phenotypes4,5.
These studies used a variety of designs, including evalua-
tion of small families of affected relatives6e12, twins13, and
sib-pairs14. So far, many of these genetic loci have been
speciﬁc to particular populations, suggesting that pheno-
typic and ethnic variability may complicate the identiﬁcation
of OA susceptibility genes. Considering the challenge of the
phenotypic heterogeneity of OA, we exploited a highly
unique extended family-based design. The CARRIAGE
(CARolinas Region Interaction of Aging, Genes and Envi-
ronment) family is one of the most extensively pedigreed
existing families in the USA comprising nine generations
originating from one founder born in the 1700s in North Car-
olina. The ethnic origin of this family is primarily African and
Native American. We posited that linkage analysis in this
relatively homogeneous large family would provide greater
power to identify OA susceptibility genes.
One of the goals of the CARRIAGE family study is to iden-
tify novel genes or replicate known genes associated with
OA susceptibility and progression. In the health fair type
setting of our family ascertainment, we could identify cases
on the basis of clinical examination but not radiograph.
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the prospect of powerful tools with which to quantify OA
burden. We therefore chose to evaluate seven OA bio-
markers to understand, prior to their use as quantitative
traits of OA, their relationship to clinical OA in this parti-
cular family. Seven biomarkers were investigated in this
large multigenerational family including: HA (hyaluronan),
COMP (cartilage oligomeric matrix protein), PIIANP
(type IIA collagen N-propeptide), CPII (type II procollagen
carboxy-propeptide), C2C (neoepitope from cleavage of
CII), hs-CRP (high-sensitivity C-reactive protein) and GSP
(glycated serum protein). Several of these markers already
fulﬁlled OA-related criteria for two or more categories of the
BIPED (Burden of disease, Investigational, Prognostic,
Efﬁcacy of therapy, and Diagnostic) classiﬁcation scheme15
matching the following categories: HA e B, P; COMP e D,
B, P; PIIANP e B, P, D; CPII e P, E, D; C2C e P, E, D
16,17.
Although six of the seven biomarkers chosen for this study
have been validated previously against radiographic OA
criteria, no previous study attempted to estimate the asso-
ciation between these biomarkers and clinical OA criteria.
To our knowledge, this is the ﬁrst evidence for an associa-
tion of OA biomarkers and hand OA based on physical ex-
amination alone.MethodsSTUDY POPULATIONThe CARRIAGE family study is a prospective family-based longitudinal
study of the interactions between aging, genetic susceptibility, and environ-
mental risk on the development of several age-related and chronic diseases
including OA, cardiovascular disease, and eye disease (glaucoma and mac-
ular degeneration). The extended family described here consists of 3357
pedigreed members dating back nine generations in the USA. Pedigree
data were obtained from three sources: (1) a book detailing the genealogy
of the descendents of this forefather; (2) family history questionnaires distrib-
uted by mail and completed during the family reunions; and (3) genealogy
data collected by a family member. These data were combined using Prog-
enyª software for genetic database and pedigree management. We were
able to successfully document 3327 family members from the nine genera-
tions, with 2795 family members completely connected to the original founder.CLINICAL ASCERTAINMENTAscertainment of 365 members, 18 years of age and older, was accom-
plished at three family reunions between 2002 and 2006 and included blood
sampling (n¼ 350), ascertainment of extensive general medical history
(n¼ 365), measurement of body mass index [BMI (n¼ 309)], self-report of
joint symptoms (pain, aching, stiffness most days) of the hands, knees,
hips, spine, ankles, big toe, shoulders, elbows, and wrists (n¼ 341), and
Rheumatologist-performed hand physical examinations for OA (n¼ 278).
Two participants were found to have credible evidence for a diagnosis for
rheumatoid arthritis (RA) and were excluded from these analyses. Additional
objective measures collected included: anthropometric data (weight and
height), blood pressure, calcaneal bone mineral density using a Norland
Apollo DEXA, ophthalmologic slit lamp examinations, and physical function
testing in members 65 years of age and over. Written informed consent was
obtained from each participant and the study was conducted with the
approval of the Duke Institutional Review Board. All information and work
was conducted under a Federal Certiﬁcate of Conﬁdentiality to ensure the
privacy of each participating member’s clinical and genetic data.DEFINITIONS OF HAND OAHand OA was deﬁned according to three deﬁnitions: ACR (American
College of Rheumatology) criteria18, GOGO (Genetics of Generalized OA)
criteria14, and any single hand joint involvement. We used modiﬁed ACR
criteria consisting of (1) hard tissue enlargement of two or more of 10 se-
lected joints; (2) hard tissue enlargement of two or more DIP joints; and
(3) fewer than three swollen metacarpophalangeal (MCP) joint; of note,
hand symptoms were not required. The GOGO criteria for determining
hand OA affection status consisted of (1) a minimum of three joints bony en-
largement [of distal interphalangeal (DIP) or proximal interphalangeal (PIP)joints] or carpometacarpal (CMC-1) squaring, and two of the three joints in-
volving the same joint group; (2) bony enlargement of at least one DIP of
digits 2e5; (3) bilateral hand involvement; (4) no more than three swollen
MCPs. Any single joint involvement was deﬁned as hard tissue enlargement
of any DIP or PIP or CMC-1 squaring. Participant group status was assigned
on the basis of clinical hand examination as either hand OA or non-hand
OA. The non-hand OA group had symptoms (pain, aching or stiffness on
most days in the last year) in at least one joint system in the body; the con-
trol group had neither clinical hand OA nor symptoms in any joint system.SERUM BIOMARKER ANALYSESBlood samples were processed, aliquoted, and stored within 4 h of collec-
tion at 80C until biomarker analyses were performed. Serum biomarker
analyses were repeated as necessary for samples with a >15% coefﬁcient
of variation (CV).
COMP
COMP was measured by an in-house ELISA method as previously de-
scribed19,20, using monoclonal antibodies 17C10 and 16F12 against human
COMP. The minimum detection limit is 120 ng/ml. Intra-assay and inter-
assay CVs were <5.8% and 8.7%, respectively.
HA
HA was measured by enzyme-linked binding protein assay (Corgenix Inc.,
Westminster, CO, USA). The assay uses enzyme-conjugated hyaluronic
acid binding protein (HABP) from bovine cartilage to speciﬁcally capture
HA from human serum. The minimum detection limit is established at
10 ng/ml. Intra-assay and inter-assay CVs were <4.7% and 7.0%,
respectively.
PIIANP
PIIANP, a marker of a fetal form of collagen II recapitulated in OA, was
measured by competitive ELISA (LINCO Research, St. Charles, MO,
USA). The minimum detection limit is 17.2 ng/ml. Intra-assay and inter-assay
CVs were <6.6% and 7.8%, respectively.
CPII
CPII, a marker of the adult form of collagen II synthesis, was measured by
competitive ELISA (IBEX, Montreal, Quebec, Canada). The minimum detec-
tion limit is estimated to be 35.1 ng/ml. Intra-assay and inter-assay CVs were
<3.7% and 9.1%, respectively.
C2C
A competitive ELISA (IBEX) was used to measure the neoepitope pro-
duced by the cleavage of type II collagen (C2C). The minimum detection limit
is reported as 7.3 ng/ml. Intra-assay and inter-assay CVs are <2.4% and
9.5%, respectively.
hs-CRP
hs-CRP was detected by a solid-phase sandwich ELISA (MAGIWEL; UBI,
Mountain View, CA, USA). The minimum detection limit is estimated to be
0.35 ng/ml. Intra-assay and inter-assay CVs were <3.9% and 8.5%,
respectively.
GSP
We quantiﬁed GSP to measure non-enzymatic glycation. In contrast to
hemoglobin A1c (HbA1c), which requires fresh blood for analysis, GSP
can be measured in frozen sera. GSP was measured by a speciﬁc enzymatic
method (DIAZYME) based on direct assessment of fructosamine in serum21
with colorimetric detection. An assay sensitivity of 30 mmol/l is reported by
the manufacturer. Intra-assay and inter-assay CVs were <2% and <3%,
respectively.
Statistical analysis
Biomarker data were natural logarithm transformed to meet assumptions
of normal distribution of the data for parametric statistical analysis, performed
using GraphPad Prism (GraphPad software, San Diego, CA, USA) and JMP
(SAS, Cary, NC, USA) software. Results were analyzed using One-way
ANOVA with TukeyeKramer multiple comparison post-hoc test. Pearson
correlation was performed to evaluate for correlation among the biomarkers.
Table I
Demographic characteristic of the 341 participants with joint symptom data
Characteristic Female (n¼ 229) Male (n¼ 112)
Age, mean standard deviation [SD (range)], years 54.87 15.69 (18e92) 53.31 15.14 (17e85)
BMI, meanSD (range), kg/m2 30.60 6.69 (18.80e60.30) (n¼ 205) 30.90 5.98 (19.90e52.00) (n¼ 104)
Subjective joint complaints
Hand symptoms 36 (15.7%) 15 (13.4%)
Knee symptoms 69 (30.1%) 42 (37.5%)
Hip symptoms 39 (17.0%) 12 (10.7%)
Spine symptoms 98 (42.8%) 32 (28.6%)
Ankle symptoms 35 (15.3%) 12 (10.7%)
Shoulder symptoms 66 (28.8%) 23 (20.5%)
Elbow symptoms 20 (8.7%) 7 (6.3%)
Big toe symptoms 18 (7.9%) 1 (0.9%)
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All 10 of the major family branches were sampled and in-
cluded both descendants of the original founder and mar-
ried-in members of the family. The baseline characteristics
for the 341 participants with available joint symptom data
are shown in Table I. Two-thirds of the participants were
women. Age and BMI were similar for women and men as
were subjective symptoms of the hand joints. Subjective
joint complaints were only dissimilar by sex for the spine
and big toe.BIOMARKERS AND HAND PHENOTYPESTable II
Hand OA and biomarkers (unadjusted)
Hand OA Non-hand OA Controls
Modiﬁed hand
ACR criteria
n¼ 36 n¼ 190 n¼ 45
ln HA 4.18 0.87**þþ 3.57 0.89** 3.07 1.04
ln COMP 7.51 0.41* 7.43 0.45 7.30 0.48
ln PIIANP 7.20 0.54 7.10 0.50* 7.29 0.53
ln CPII 7.17 0.38 7.03 0.41 7.06 0.43
ln C2C 5.39 0.22 5.36 0.26 5.35 0.28
ln hs-CRP 8.26 1.45 8.28 1.44** 7.68 1.16
ln GSP 5.44 0.22 5.42 0.25* 5.34 0.21
Age, years 67.7 12.0**þþ 55.9 13.8** 48.3 12.8
GOGO hand
criteria
n¼ 41 n¼ 185 n¼ 45
ln HA 4.09 0.86**þþ 3.56 0.90** 3.07 1.04
ln COMP 7.51 0.38* 7.42 0.45 7.30 0.48
ln PIIANP 7.15 0.53 7.10 0.50* 7.29 0.53
ln CPII 7.10 0.38 7.04 0.41 7.06 0.43
ln C2C 5.40 0.23 5.36 0.26 5.35 0.28
ln hs-CRP 8.23 1.44 8.29 1.44** 7.68 1.16
ln GSP 5.41 0.22 5.43 0.26* 5.34 0.21
Age, years 67.1 12.2**þþ 55.6 13.9** 48.3 12.8
Any single hand
joint involvement
n¼ 108 n¼ 118 n¼ 45
ln HA 3.87 0.84**þþ 3.49 0.94** 3.07 1.04
ln COMP 7.50 0.41** 7.38 0.46 7.30 0.48
ln PIIANP 7.09 0.50* 7.14 0.52 7.29 0.53
ln CPII 7.07 0.43 7.03 0.39 7.06 0.43
ln C2C 5.38 0.26 5.35 0.26 5.35 0.28Six of the seven serum biomarkers analyzed were cho-
sen on the basis of literature evidence suggesting some
association with OA. To avoid potential confounding by
high cartilage turnover due to other arthropathies or by car-
tilage growth plate metabolism, we excluded two partici-
pants with RA and the ﬁve participants younger than 25
years of age. Seven serum biomarkers were analyzed for
the 271 skeletally mature participants with available hand
examination data and sera. Mean ln serum HA, COMP,
and C2C were consistently higher in the hand OA group
than the non-hand OA and control groups for all deﬁnitions
of hand OA (Table II). This difference was signiﬁcant for
HA (all deﬁnitions), hs-CRP (all deﬁnitions) and COMP
(any single hand joint involvement deﬁnition). In addition,
hs-CRP was signiﬁcantly higher in hand OA and non-
hand OA (with joint symptoms) than controls, with the
strength of the association varying by hand OA deﬁnition.
Overall, ﬁve of the seven biomarkers increased signiﬁ-
cantly with age: HA (r¼ 0.57, P< 0.0001), COMP
(r¼ 0.33, P< 0.0001), PIIANP (r¼ 0.20, P¼ 0.0011), C2C
(r¼ 0.16, P¼ 0.0016), and hs-CRP (r¼ 0.12, P¼ 0.048).
When adjusted for age and sex, the collagen synthesis
marker, PIIANP, was signiﬁcantly lower in the hand OA
group compared with the control group for all deﬁnitions of
hand OA. After age and gender adjustment, the difference
in HA among groups was marginally signiﬁcant (ANOVA
P¼ 0.08). The age and gender adjusted ratio of HA/PIIANP
reﬂected a signiﬁcant excess of cartilage degradation over
synthesis in the hand OA group and non-hand OA (with joint
symptoms) group compared with control (Table III).ln hs-CRP 8.32 1.54** 8.24 1.35* 7.68 1.16
ln GSP 5.43 0.25 5.43 0.24* 5.34 0.21
Age, years 63.7 12.1**þþ 52.3 13.9** 48.3 12.8BIOMARKERS AND HAND SYMPTOMS
Values are meanSD, *P< 0.1 and **P< 0.05 comparing hand
OA or non-hand OA with controls; þþP< 0.05 comparing hand OA
and non-hand OA.A total of 120 participants reported joint symptoms in the
hand or in another joint system but did not meet the deﬁni-
tion of clinical hand OA based on even the least stringentcriterion (any single joint involvement). This group was fur-
ther subdivided into those with hand symptoms symp-
toms elsewhere (Group A), and those without hand
symptoms but with symptoms outside the hand (Group B).
We compared these two groups with controls (Group C)
to discern potential biomarkers of early OA. ln GSP was sig-
niﬁcantly higher in those with hand symptoms compared
with controls (Fig. 1). After adjustment for diabetes history,
ln GSP was signiﬁcantly higher in those with hand symp-
toms compared with controls (P¼ 0.039). ln HA, and the
ratio of HA to collagen synthesis (HA/PIIANP) was signiﬁ-
cantly higher in those with symptoms outside the hand
(Group B) compared with controls.
Table III
Hand OA and biomarkers (mean values adjusted for age and/or gender)
Hand OA Non-hand OA Controls P value
(adjusted
for age)





n¼ 36 n¼ 190 n¼ 45 n¼ 36 n¼ 190 n¼ 45
ln HA 3.77 0.82 3.58 0.78 3.36 0.80 0.08 3.79 0.84 3.60 0.89 3.37 0.84 0.08
ln PIIANP 7.10 0.52 7.10 0.50 7.36 0.51 0.01 7.04 0.54 7.06 0.56 7.31 0.53 0.01
ln HA/PIIANP 0.53 0.12 0.50 0.11 0.45 0.12 0.01 0.53 0.12 0.51 0.13 0.45 0.12 0.01
GOGO hand
criteria
n¼ 41 n¼ 185 n¼ 45 n¼ 41 n¼ 185 n¼ 45
ln HA 3.70 0.82 3.59 0.77 3.36 0.80 0.1 3.71 0.86 3.61 0.88 3.38 0.84 0.1
ln PIIANP 7.04 0.52 7.11 0.49 7.36 0.51 0.01 6.99 0.54 7.07 0.56 7.31 0.53 0.01
ln HA/PIIANP 0.52 0.12 0.50 0.11 0.45 0.12 0.02 0.53 0.12 0.51 0.13 0.46 0.12 0.02
Any single hand
joint involvement
n¼ 108 n¼ 118 n¼ 45 n¼ 108 n¼ 118 n¼ 45
ln HA 3.59 0.83 3.63 0.83 3.37 0.81 0.2 3.60 0.90 3.64 0.87 3.39 0.84 0.2
ln PIIANP 7.01 0.53 7.18 0.53 7.37 0.51 0.0006 6.97 0.56 7.14 0.54 7.32 0.53 0.0007
ln HA/PIIANP 0.51 0.12 0.50 0.12 0.46 0.12 0.02 0.52 0.13 0.51 0.12 0.46 0.12 0.02
Values are mean SD.
Fig. 1. Biomarkers and hand symptoms. The individuals without clinical hand OA (on the basis of a negative hand joint examination) were
categorized into three groups: Group A (n¼ 18) e no hand OA by examination, presence of hand symptoms, and possible symptoms in other
joint systems; Group B (n¼ 57) e no hand OA by examination, no hand symptoms, but joint symptoms in one or more other joint systems;
Group C (n¼ 45) e no hand OA by examination, no hand symptoms, and no other joint symptoms. Box plots depict mean, 25th and 75th
percentiles, and minimum and maximum. *P< 0.1, **P< 0.05.
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Table IV
Correlations among the serum biomarkers
Biomarkers ln HA ln COMP ln C2C ln CPII ln PIIANP ln hs-CRP
ln COMP 0.3498***
ln C2C 0.2611*** 0.0858
ln CPII 0.2154*** 0.0904 0.4434***
ln PIIANP 0.1976*** 0.0685 0.3071*** 0.2984***
ln hs-CRP 0.0819 0.0472 0.0575 0.0528 0.0959*
ln GSP 0.1445** 0.2638*** 0.0344 0.0254 0.0369 0.0454
Correlation coefﬁcients were determined by Pearson correlation; *P< 0.05, **P< 0.01, ***P< 0.0001.
1058 H.-C. Chen et al.: Biomarkers of hand OACORRELATIONS AMONG THE BIOMARKERSAll of the biomarkers, except hs-CRP, correlated with HA
(Table IV). There was a signiﬁcant correlation between
COMP and GSP. Not surprisingly, there were strong corre-
lations among the type II collagen biomarkers (PIIANP,
CPII, and C2C).Discussion
We have been able to ascertain multiple members of
a large extended family for the purposes of evaluating
aging, environmental, and genetic risk for OA. Most previ-
ous studies of biomarkers and OA were focused on knees
and hips and have relied on radiographs. However, com-
pared with knee or hip OA, hand OA is easier to evaluate
by physical examination and has been reported to display
stronger concordance and familial aggregation. The reunion
venues at which these individuals were assessed afforded
the possibility of blood collection and limited musculoskele-
tal examinations, but not radiographic assessment. Based
on the strength of past radiographic validation of a number
of OA-related biomarkers, we hypothesized that biomarkers
could be used as quantitative traits of OA. Our goal there-
fore, in this study, was to evaluate the strength of associa-
tion of known OA-related biomarkers to the clinical OA data
available in this family.
The ethnic composition of this family is a unique mixture
of mainly African and Native American. With a few excep-
tions20,22, the majority of OA biomarker validation studies
have been performed in Caucasians. This study is there-
fore novel for speciﬁcally evaluating the strength of associ-
ation between the clinical OA phenotypes and OA-related
biomarkers in a non-Caucasian family. This study demon-
strated the feasibility of this goal in that we identiﬁed four
biomarkers, HA, COMP, PIIANP, and GSP, that were as-
sociated with hand OA in this family on the basis of clinical
examination or hand symptoms. To our knowledge, this is
the ﬁrst report of an association of OA-related biomarkers
and hand OA based upon physical examination data
alone.
We observed lower PIIANP values in association with
hand OA. Although Sharif et al. reported that serum PIIANP
was higher in knee OA progressors compared with non-
progressors, theirs was a community-based cohort with rel-
atively mild knee OA23; most of the previous studies have
demonstrated that serum PIIANP was decreased in patients
with knee OA compared to controls24e26.
We observed an increase in HA and COMP in associa-
tion with hand OA. In the Johnston County OA biomarkers
sub-studies, serum COMP and HA increased signiﬁcantly
with knee and hip OA, even after adjustment for other risk
factors including age19,20. The association of serum HAand COMP with hand OA in our cohort was not independent
of age. These results may partially arise from the direct
comparison of highly sensitive biomarkers with only moder-
ately sensitive physical examination criteria without any
supporting radiographs.
Joint symptoms in the absence of clinical examination
ﬁndings may be an indicator of early OA. We observed
higher levels of hs-CRP and GSP in the group with hand
symptoms but no hand OA by physical examination.
Thus, our data suggest that hs-CRP and GSP may be bio-
markers of early sub-clinical hand OA; this possibility has
been suggested by several other studies of hs-CRP27,28.
We assessed GSP as an intermediate to advanced glyca-
tion end product (AGE). AGEs are formed by non-enzy-
matic reactions in the process of post-translational
modiﬁcation, have been involved in the aging process
and the pathogenesis of several diseases, including RA
and diabetes. A recent study showed that accumulation
of AGEs is a potential risk factor for OA29. Verzijl et al.
also showed that AGE crosslinking may result in pathologic
stiffness of cartilage in vitro30. Senolt et al. reported an
increased serum concentration of pentosidine, a form of
AGE, in patients with knee OA. In addition, he found a sig-
niﬁcant correlation between synovial ﬂuid COMP and
serum pentosidine (R2¼ 0.11, P< 0.05)31. In our study,
GSP was correlated with serum COMP (R2¼ 0.26,
P< 0.0001) along with HA (R2¼ 0.14, P< 0.0001). A larger
sample size, or more sensitive phenotyping methods,
may be required to see an association between GSP and
OA.
A potential limitation of this study was the inability to con-
duct radiographic phenotyping due to the health fair type
setting of the ascertainment venues. We also have knee ex-
amination data on only 120 individuals as this aspect of the
study was only added in 2006. Therefore, this, as other
studies, could be confounded by cartilage degradation at
other joint sites for which clinical examination data were
unavailable. Nevertheless, we have self-reported arthritis
symptoms on all participants for all joint sites. Moreover,
our study was community-based and therefore not selected
for OA. In this way, it is potentially more representative of
the population at large although healthier family members
were probably more likely to participate.
In summary, we report the ﬁrst evidence for an associa-
tion of OA biomarkers and clinical hand OA. Several of
the biological markers (HA, COMP, PIIANP, hs-CRP,
GSP, and HA/PIIANP) evaluated in this large family showed
an association with clinical phenotypes of hand OA or hand
symptoms. This study design offers the prospect of minimiz-
ing genetic heterogeneity through the analysis of a large
family, and demonstrates the feasibility of utilizing several
OA-related biomarkers as quantitative traits to identify un-
derlying OA genes in this family.
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